Betulin Suppresses Osteoclast Formation via Down-Regulating NFATc1

Journal of Clinical Medicine

SangHyun Sung¹  Yongjin Lee²  Hae-Gwang Hwang²  Young-Jin Son²  Kwang-Jin Kim²  Mina Lee² 

[1] College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Gwanak-gu, Seoul 08826, Korea;Department of Pharmacy, Sunchon National University, Jeonnam, Suncheon 57922, Korea;

关键词: bone;    osteoporosis;    osteoclast;    RANKL;    NFATc1;    betulin;    natural product;    Betula platyphylla;   

DOI  :  10.3390/jcm7060154

来源: DOAJ

【 摘 要 】

Osteoporosis is a disease characterized by osteoclast-mediated low bone mass. The modulation of osteoclasts is important for the prevention or therapeutic treatment of loss of bone mass. Osteoclasts, which are bone-resorbing multinucleated cells, are differentiated from the hematopoietic stem cell monocyte/macrophage lineage by Receptor activator of nuclear factor kappa-B ligand (RANKL) expressed from osteoblasts and stromal cells. RANKL signaling ultimately activates nuclear factor of activated T Cells 1 (NFATc1), which is a master transcription factor in osteoclastogenesis. Betulin, a lupine type pentacyclic triterpenoid, was isolated from the bark of Betula platyphylla. Betulin inhibited RANKL-mediated osteoclast differentiation by downregulating NFATc1. Betulin may serve as a useful structural scaffold in the therapeutic agent development to prevention/treatment the osteoclast-mediated bone disorder.

【 授权许可】

Unknown